Halozyme Therapeutics 1Q Loss Widens On Costs
Stock quotes in this article:
HALO
SAN DIEGO (AP) Biopharmaceutical company Halozyme Therapeutics Inc. said Friday it posted a wider first-quarter loss due to higher research and development spending.
The company lost $14.7 million, or 18 cents per share, compared with a loss of $10 million, or 13 cents per share, during the same period a year prior. Revenue, which comes from partnerships, rose 54 percent to $2.8 million from $1.8 million. Analysts polled by Thomson Reuters expected a loss of 16 cents per share on revenue of $3.2 million. Expenses jumped 39 percent to $17.5 million. Shares of Halozyme rose 19 cents, or 3.3 percent, to $6 in morning trading. The stock has traded between $2.60 and $8.26 over the last 52 weeks.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,389.96 | 1,106.29 | 2,194.60 | 34.83 |
Oil *
77.64
|
|
UP
23.81
|
UP
6.37
|
UP
21.46
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.32
|
|
+0.23%
|
+0.58%
|
+0.99%
|
+3.05%
|
Data delayed 20 minutes |
